文献速递消化系统肿瘤

靶向Claudin 18.2的抗体药物偶联物CMG901治疗晚期胃癌或胃食管结合部癌(KYM901):多中心、开放标签、单臂、1期试验

Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.
PubMed 文献 · Lancet Oncol · 2025-01-06

KYM901是一项在中国31家医院开展的多中心、开放标签、单臂1期试验,评估CMG901在晚期实体瘤(含胃癌或胃食管结合部癌及胰腺癌)患者中的抗肿瘤活性与安全性。剂量递增阶段27例,剂量扩展阶段107例胃癌或胃食管结合部癌患者;2·2–3·0 mg/kg队列中113例胃癌或胃食管结合部癌患者的确认客观缓解率为28%(95% CI 20–38;113例中32例),安全性总体可控,2·2 mg/kg被提议为2期推荐剂量。

要点

  • CMG901在晚期胃癌或胃食管结合部癌中确认客观缓解率为28%(95% CI 20–38;113例中32例)。
  • 剂量扩展阶段107例中,3级或以上治疗中出现的不良事件发生于73例(68%),严重不良事件54例(50%)。
  • 基于总体安全性、活性和药代动力学,2·2 mg/kg被提议为2期推荐剂量。

核心结论

  • CMG901在晚期胃癌或胃食管结合部癌患者中显示可控的安全性特征和良好的抗肿瘤活性。

研究设计与样本

  • KYM901为多中心、开放标签、单臂1期试验,包括剂量递增和剂量扩展阶段,在中国31家医院招募晚期实体瘤患者。
  • 剂量递增阶段纳入27例患者,剂量扩展阶段纳入107例胃癌或胃食管结合部癌患者。
  • 患者每3周静脉给予CMG901(剂量递增0·3–3·4 mg/kg,剂量扩展2·2–3·0 mg/kg),直至疾病进展、不可接受的毒性、开始新的抗肿瘤治疗、退出研究或死亡。
  • 主要终点为剂量递增阶段的不良事件和剂量限制性毒性,以及剂量扩展阶段的客观缓解率和2期推荐剂量。

主要发现

  • 截至2024年2月24日,剂量递增阶段在2·2 mg/kg时发生1例剂量限制性毒性(3级胰腺炎),未达到最大耐受剂量。
  • 剂量递增阶段27例患者均报告至少1例治疗中出现的不良事件,最常见为呕吐19例(70%)、食欲下降16例(59%)、蛋白尿16例(59%)和贫血15例(56%);5例(19%)发生药物相关3级或以上治疗中出现的不良事件。
  • 剂量扩展阶段107例患者中,3级或以上治疗中出现的不良事件发生于73例(68%),严重不良事件发生于54例(50%);最常见的3–4级不良事件为中性粒细胞计数降低22例(21%)、贫血15例(14%)和呕吐11例(10%);报告1例治疗相关死亡。
  • 中位随访9·0个月(IQR 4·4–12·9),剂量递增和剂量扩展阶段2·2–3·0 mg/kg队列全分析集113例胃癌或胃食管结合部癌患者的确认客观缓解率为28%(95% CI 20–38;113例中32例)。
  • 疗效分析集109例患者的确认客观缓解率为29%(95% CI 21–39;109例中32例)。

关键数值与推荐

  • 确认客观缓解定义为初始评估后至少4周随访影像验证的部分缓解或完全缓解。
  • 安全性在所有接受至少1剂CMG901并至少进行1次给药后安全性评估的患者中评估。
  • 抗肿瘤活性在所有接受至少1剂CMG901的患者(全分析集)以及所有接受CMG901治疗、至少进行1次给药后影像评估且无重大方案偏离的患者(疗效分析集)中评估。

临床怎么用

  • 基于总体安全性、活性和药代动力学,2·2 mg/kg被提议为2期推荐剂量。
  • 胰腺癌患者的剂量扩展数据将另行发表;其他实体瘤患者(n=2)因样本量小不计划发表。

局限性

  • 其他实体瘤患者(n=2)因样本量小,结果不计划发表。
  • 胰腺癌患者的剂量扩展数据将另行发表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CMG901 is a novel first-in-class antibody-drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the antitumour activity and safety of CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer and other solid tumours. METHODS: KYM901 is a multicentre, open-label, single-arm, phase 1 trial consisting of dose-escalation and dose-expansion stages. Patients with advanced solid tumours, including gastric or gastro-oesophageal junction and pancreatic cancers, were recruited from 31 hospital sites in China. Eligible patients were aged 18 years or older, were refractory to standard therapy or had no available standard-of-care regimen, and had an Eastern Cooperative Oncology Group performance status score of 0-1, a life expectancy of at least 3 months, and at least one measurable lesion. Patients received intravenous CMG901 every 3 weeks (0·3-3·4 mg/kg in dose escalation and 2·2-3·0 mg/kg in dose expansion) until disease progression, unacceptable toxic effects, initiation of new antitumour therapy, study withdrawal, or death. Primary endpoints were adverse events and dose-limiting toxic effects in the dose-escalation phase, and objective response rate and recommended phase 2 dose in the dose-expansion phase. Confirmed objective response was defined as a partial or complete response that was verified by follow-up imaging at least 4 weeks after the initial assessment. Safety was assessed in all patients who received at least one dose of CMG901 with at least one post-dose safety evaluation. Antitumour activity was assessed in all patients who received at least one dose of CMG901 (full analysis set) and in all CMG901-treated patients with at least one post-dose imaging evaluation and no major protocol deviations (efficacy analysis set). Dose-expansion data for patients with pancreatic cancer will be published separately. Due to small sample sizes, results in patients with other solid tumours (n=2) are not planned for publication. This ongoing trial is registered with ClinicalTrials.gov, NCT04805307. FINDINGS: Between Dec 24, 2020, and Feb 23, 2023, 27 patients were enrolled in the dose-escalation phase (median age 57·0 years [IQR 48·0-63·0]; 14 [52%] male, 13 [48%] female) and 107 patients with gastric or gastro-oesophageal junction cancer in the dose-expansion phase (median age 56·0 years [44·0-64·0]; 57 [53%] male, 50 [47%] female). As of Feb 24, 2024, one dose-limiting toxic effect (grade 3 pancreatitis) occurred at 2·2 mg/kg, and the maximum tolerated dose was not reached in the dose-escalation phase. All 27 patients reported at least one treatment-emergent adverse event, most frequently vomiting (19 [70%]), decreased appetite (16 [59%]), proteinuria (16 [59%]), and anaemia (15 [56%]), and five (19%) had drug-related grade 3 or worse treatment-emergent adverse events. In 107 patients, grade 3 or worse treatment-emergent adverse events occurred in 73 (68%) patients and serious adverse events occurred in 54 (50%) patients in dose expansion. The most common grade 3-4 adverse events were neutrophil count decreased (22 [21%]), anaemia (15 [14%]), and vomiting (11 [10%]). One treatment-related death was reported. At median follow-up of 9·0 months (IQR 4·4-12·9), among 113 patients with gastric or gastro-oesophageal junction cancer in the 2·2-3·0 mg/kg cohort full analysis set across both the dose-escalation and dose-expansion phases, the confirmed objective response rate was 28% (95% CI 20-38; 32 of 113 patients). In the 109 patients included in the efficacy analysis set, the confirmed objective response rate was 29% (95% CI 21-39; 32 of 109 patients). Based on overall safety, activity, and pharmacokinetics of CMG901, 2·2 mg/kg was the proposed recommended phase 2 dose. INTERPRETATION: CMG901 showed a manageable safety profile and had promising antitumour activity in patients with advanced gastric or gastro-oesophageal junction cancer. FUNDING: KYM Biosciences.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Ruan DY, Liu FR, Wei XL, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025. PMID: 39788133. doi:10.1016/S1470-2045(24)00636-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。